Literature DB >> 1586506

Effect of dipyridamole, theophyllamine and verapamil on spontaneous in vitro proliferation of myelogenous leukaemia cells.

O Bruserud1.   

Abstract

Dipyridamole strongly inhibited spontaneous in vitro proliferation of peripheral blood mononuclear cells from patients with acute myelogenous leukaemia (n = 9), chronic myelogenous leukaemia in first chronic phase (n = 4) and blast phase (n = 1). Theophyllamine and verapamil also inhibited proliferation of leukaemia cells from all patients except the CML patient in blast phase where only minimal inhibition was seen. Only dipyridamole caused strong inhibition in concentrations corresponding to the therapeutic serum level, and this inhibition was not influenced by the presence of high levels of interleukin 2.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1586506     DOI: 10.3109/02841869209088266

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  7 in total

1.  In vitro effect of r-verapamil on acute myelogenous leukemia blast cells: studies of cytokine secretion and cytokine-dependent blast proliferation.

Authors:  O Bruserud; I Nesthus; G Pawelec
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

2.  Connexin expression in human acute myeloid leukemia cells: identification of patient subsets based on protein and global gene expression profiles.

Authors:  Håkon Reikvam; Anita Ryningen; Lars Rune Sæterdal; Ina Nepstad; Brynjar Foss; Øystein Bruserud
Journal:  Int J Mol Med       Date:  2014-12-19       Impact factor: 4.101

Review 3.  Targeting the two-pore channel 2 in cancer progression and metastasis.

Authors:  Kathryn A Skelding; Daniel L Barry; Danielle Z Theron; Lisa F Lincz
Journal:  Explor Target Antitumor Ther       Date:  2022-02-28

4.  Inhibition of Mammalian target of rapamycin in human acute myeloid leukemia cells has diverse effects that depend on the environmental in vitro stress.

Authors:  Anita Ryningen; Håkon Reikvam; Ina Nepstad; Kristin Paulsen Rye; Oystein Bruserud
Journal:  Bone Marrow Res       Date:  2012-10-02

5.  Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells.

Authors:  Line Wergeland; Gry Sjøholt; Ingvild Haaland; Randi Hovland; Øystein Bruserud; Bjørn Tore Gjertsen
Journal:  Mol Cancer       Date:  2007-05-11       Impact factor: 27.401

6.  LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro.

Authors:  Tien-sheng Huang; Line M Myklebust; Endre Kjarland; Bjørn Tore Gjertsen; Frederic Pendino; Øystein Bruserud; Stein Ove Døskeland; Johan R Lillehaug
Journal:  Mol Cancer       Date:  2007-04-23       Impact factor: 27.401

7.  CDC25 Inhibition in Acute Myeloid Leukemia-A Study of Patient Heterogeneity and the Effects of Different Inhibitors.

Authors:  Annette K Brenner; Håkon Reikvam; Kristin Paulsen Rye; Karen Marie Hagen; Antonio Lavecchia; Øystein Bruserud
Journal:  Molecules       Date:  2017-03-11       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.